Display options
Cite
Siewertsz van Reesema LL, Lee MP, Zheleva V, et al. RAS pathway biomarkers for breast cancer prognosis. Clin Lab Int. 2016;40:18-23
Siewertsz van Reesema, L. L., Lee, M. P., Zheleva, V., Winston, J. S., O'Connor, C. F., Perry, R. R., Hoefer, R. A., & Tang, A. H. (2016). RAS pathway biomarkers for breast cancer prognosis. Clinical laboratory international, 4018-23.
Siewertsz van Reesema, Lauren L, et al. "RAS pathway biomarkers for breast cancer prognosis." Clinical laboratory international vol. 40 (2016): 18-23.
Siewertsz van Reesema LL, Lee MP, Zheleva V, Winston JS, O'Connor CF, Perry RR, Hoefer RA, Tang AH. RAS pathway biomarkers for breast cancer prognosis. Clin Lab Int. 2016 Nov;40:18-23. PMID: 28579913; PMCID: PMC5455995.
Copy Download .nbib Format: NLM
Share it on

Clin Lab Int. 2016 Nov;40:18-23.

RAS pathway biomarkers for breast cancer prognosis.

Clinical laboratory international

Lauren L Siewertsz van Reesema, Michael P Lee, Vasilena Zheleva, Janet S Winston, Caroline F O'Connor, Roger R Perry, Richard A Hoefer, Amy H Tang

Affiliations

  1. Eastern Virginia Medical School, Norfolk, VA 23507, USA.
  2. Department of Surgery, Eastern Virginia Medical School, Norfolk, VA 23507, USA.
  3. Sentara Pathology and Pathology Sciences Medical Group, Sentara Norfolk General Hospital (SNGH), Norfolk, VA 23507, USA.
  4. Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA 23507, USA.
  5. Sentara Cancer Network, Virginia 23606, USA.
  6. Dorothy G. Hoefer Comprehensive Breast Center, Virginia 23606, USA.
  7. Sentara Care-Plex Hospital, Newport News, Virginia 23606, USA.
  8. Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA.

PMID: 28579913 PMCID: PMC5455995

Abstract

Metastatic breast cancer is a highly heterogeneous, rapidly evolving and devastating disease that challenges our ability to find curative therapies. RAS pathway activation is an understudied research area in breast cancer. EGFR/RAS pathway activation is prevalent in breast cancer with poor prognosis. The prognostic RAS pathway biomarkers can be used to identify resistant tumour clones, stratify patients and guide therapies.

References

  1. J Cancer. 2014 Jan 05;5(1):58-68 - PubMed
  2. J Clin Oncol. 2011 Jun 1;29(16):2273-81 - PubMed
  3. Surg Clin North Am. 2013 Apr;93(2):493-9 - PubMed
  4. J Natl Cancer Inst. 2008 Nov 19;100(22):1606-29 - PubMed
  5. Dis Model Mech. 2016 Feb;9(2):131-40 - PubMed
  6. N Engl J Med. 2005 Oct 20;353(16):1659-72 - PubMed
  7. N Engl J Med. 2010 Nov 11;363(20):1938-48 - PubMed
  8. Crit Rev Oncol Hematol. 2011 Dec;80(3):433-49 - PubMed
  9. Cancer. 2013 Mar 15;119(6):1140-8 - PubMed
  10. Cancer Res. 2015 Nov 15;75(22):4960-72 - PubMed
  11. Drugs. 2002;62(1):209-43 - PubMed
  12. Nature. 2002 Jan 31;415(6871):530-6 - PubMed
  13. Breast Cancer Res. 2015 Jan 27;17:11 - PubMed
  14. Cancer Res. 2014 Jun 1;74(11):2913-21 - PubMed
  15. N Engl J Med. 2005 Oct 20;353(16):1673-84 - PubMed
  16. Clin Cancer Res. 2015 Apr 15;21(8):1797-801 - PubMed
  17. Ann Surg Oncol. 2015 May;22(5):1408-15 - PubMed
  18. J Clin Oncol. 2007 Sep 1;25(25):3846-52 - PubMed
  19. Cancer Res. 2007 Dec 15;67(24):11798-810 - PubMed
  20. Nat Rev Cancer. 2009 Aug;9(8):550-62 - PubMed
  21. J Natl Compr Canc Netw. 2009 Nov;7(10 ):1060-96 - PubMed
  22. Nat Rev Clin Oncol. 2013 Apr;10(4):191-210 - PubMed
  23. J Clin Oncol. 2006 Jun 20;24(18):2786-92 - PubMed
  24. EBioMedicine. 2016 Sep;11:183-198 - PubMed
  25. CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62 - PubMed
  26. N Engl J Med. 2012 Jan 12;366(2):109-19 - PubMed
  27. Nat Rev Cancer. 2013 Oct;13(10):714-26 - PubMed
  28. Breast Cancer Res Treat. 2013 Oct;141(3):507-14 - PubMed
  29. Ann Oncol. 2006 May;17(5):818-26 - PubMed
  30. N Engl J Med. 2015 Jan 8;372(2):134-41 - PubMed
  31. Nat Rev Cancer. 2003 Jan;3(1):11-22 - PubMed
  32. Nat Rev Cancer. 2011 Oct 13;11(11):761-74 - PubMed
  33. J Natl Cancer Inst. 2011 Sep 21;103(18):1397-402 - PubMed
  34. Endocr Relat Cancer. 2010 Sep 23;17(4):R245-62 - PubMed
  35. Breast Cancer Res. 2016 Mar 09;18(1):30 - PubMed
  36. Nat Rev Clin Oncol. 2015 Jul;12(7):381-94 - PubMed
  37. J Natl Compr Canc Netw. 2013 Feb 1;11(2):174-82; quiz 182 - PubMed
  38. Nat Rev Clin Oncol. 2010 Dec;7(12):669-70 - PubMed
  39. J Clin Oncol. 2016 Feb 20;34(6):611-35 - PubMed
  40. Science. 2013 Mar 29;339(6127):1546-58 - PubMed
  41. Nat Rev Clin Oncol. 2015 Jun;12(6):335-43 - PubMed
  42. Nat Rev Cancer. 2013 Sep;13(9):663-73 - PubMed
  43. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  44. Nat Rev Clin Oncol. 2010 Dec;7(12):725-32 - PubMed
  45. J Clin Oncol. 2010 Jun 1;28(16):2784-95 - PubMed
  46. Cancer Treat Rev. 2008 Jun;34(4):378-90 - PubMed
  47. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32 - PubMed
  48. Breast Cancer Res Treat. 2014 Sep;147(2):407-14 - PubMed
  49. N Engl J Med. 2015 Nov 19;373(21):2005-14 - PubMed

Publication Types

Grant support